Of the 110 patients who were excluded 60 were HER2+, 37 were triple-negative, 4 patients received CT concomitantly with HT as first-line treatment, 4 patients had a second non-breast tumor before the diagnosis of MTS and 2 patients did not receive any systemic therapy for their disease. This evidence concerns the gene ERBB2 and deafness dystonia syndrome.